Encouraging collaboration in pharma
Wendy Adams discusses Galderma’s three business units, raising funds for kids with skin conditions, and encouraging collaboration through meetings (877 words, 4 minutes)
NPC Healthbiz Weekly is presented to you with support from Impres, Canada’s Next Generation Commercial Partner
Galderma Canada Inc.’s structure sets it apart from its competitors, according to the company’s General Manager, Wendy Adams. “There’s not another company that has the uniqueness of an aesthetics business followed by a prescription business and a consumer business,” she said during a recent episode of the NPC Podcast. “We have different target audiences ranging from plastic surgeons, dermatologists, nurse injectors, and prescribing pharmacists.” Thornhill, Ont.-based Galderma Canada operates in three business units: aesthetics, prescription, and consumer.
Adams notes that aside from their broad target audience, Galderma’s brands are specific to dermatology and cover a variety of prescribers and users, ultimately differentiating them in the marketplace. “On top of that, we have brands in the first or second spot within their disease [category],” she says.
Adams [pictured below] says frequent meetings facilitate collaboration among the three business units. “I host meetings with all three businesses, particularly with the marketers, because they’re developing the assets to put in the hands of the sales teams,” she says. “The marketers don’t always get the time to be creative, so these sessions allow them to think more innovatively, take from the other business units. and grow within each other.”
Adams is proud of Galderma’s work supporting Camp Liberté, a summer camp for children between seven and 14 years with moderate to severe skin conditions. Every year, the company organizes the Galderma Walk around the office’s neighbourhood, and the company matches all funds raised. She sees this initiative as making sure Galderma products are used to help compassionately. “It’s been a goal of mine that we continue to raise funds and help send kids to camp,” she says. “I like to use that as a unifying point for what we all strive for because sometimes people are caught up in the numbers.”
She adds that when people are caught up in the numbers, they don’t always remember how their products help physicians and patients. She says it is essential to hear from both, to tie their vision together. “We have the patients who send in stories about how the products are helping them or how we’ve helped their disease state,” she says. She adds that Galderma often hears from grateful parents whose kids were able to attend summer camp for the first time thanks to the company’s support of Camp Liberté.
THIS WEEK 08/01/23
The U.S. FDA has approved Tarsus Pharmaceuticals’ lotilaner ophthalmic solution (Xdemvy) for treating Demodex blepharitis.
Amylyx Pharmaceuticals Canada announced it entered into a Product Listing Agreement with New Brunswick for the public reimbursement of the company’s sodium phenylbutyrate and ursodoxicoltaurine (Albrioza) for the treatment of amyotrophic lateral sclerosis (ALS).
Health Canada approved AbbVie’s upadacitinib (Rinvoq) for Tx of moderately to severely active ulcerative colitis in adult patients.
Biocon Biologics announced the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of an aflibercept biosimilar (Yesafili) for the treatment of neovascular age-related macular degeneration, visual impairment due to macular edema secondary to retinal vein occlusion, visual impairment due to diabetic macular edema and visual impairment due to myopic choroidal neovascularization.
LISTEN UP
In season 10 of the NPC Podcast, Shanil Ebrahim, Partner and National Life Sciences and Healthcare Consulting Leader at Deloitte Canada, discusses improving healthcare literacy, expanding the use and integration of healthcare data, and public-private collaborations promoting equity in healthcare. Hear him in conversation with podcast hosts Mitch Shannon, Jim Shea and Mark McElwain.
HEALTHBIZ REWIND
This feature of NPC Healthbiz Weekly looks back at some of the most insightful moments from previous NPC Podcast episodes. In Healthbiz Rewind, you’ll read bold life sci predictions made during the renowned “Prognostication Korner” segment of the NPC Podcast.
Danny Goldman
Head of Strategy and Portfolio Operations, Canada
Sanofi
Mississauga, Ont.
Season 6, episode 03
Listen to this episode here
What bold predictions will you make about the life sciences industry during the coming 12 to 24 months? [This episode was recorded in January 2022]
I would say that from an innovation standpoint, there’s still an exceptionally healthy pipeline among all or most companies, and there’s still a lot of unmet patient needs. In terms of our overall focus and objectives, I think it will continue to be on patients and delivering the proper med for the right patient at the right time. From an engagement perspective, we know things will have to change and become more of a hybrid model. I’m sure you’ve seen many surveys done in the industry that showed that since the Covid-19 pandemic began, there’s a dichotomy between physicians on whether they want to meet face-to-face or virtually. In the last two years, we’ve demonstrated that we can engage in a virtual environment, but it doesn’t replace face-to-face. For example, when you look at a field like oncology, which focuses on multidisciplinary specialist care, having various specialists in a room talking versus on Zoom is more optimal.
Lastly, I think that digital innovation and transformation are the future of Pharma. So how a company evolves over the next three to five years, and especially their strategy, and digital transformation, will be paramount in terms of how competitive we can be in the future. I think the Covid-19 pandemic accelerated the need to transform digitally and cemented that we must remain flexible, adaptable, and always ready to pivot when necessary.
Register now for the 17th Annual National Pharmaceutical Congress on Wednesday, November 22, 2023
The 17th Annual National Pharmaceutical Congress will bring the best of Canadian Pharma together. The Congress will be held on November 22, 2023, at the Mississauga Convention Centre. As Canada’s most significant stage for leaders in the pharmaceutical industry, the Congress presents industry reflections, ideas, and innovations. The Congress is attended by more than 200 delegates annually and is an opportunity to learn, reflect, and network with the industry’s most prominent thought leaders and visionaries. Register now for 50% off.
NEXT WEEK
It’s easy to get your no-charge subscription to NPC Healthbiz Weekly, and we’ll send each issue to your phone or inbox each Tuesday at 6:00 a.m. sharp.
You are receiving this newsletter because you are a client of Chronicle Companies, attended a National Pharmaceutical Congress live event or webinar, or previously requested a subscription to one of our newsletters. If you no longer wish to subscribe to this newsletter, please email the subject line “Unsubscribe NPC Healthbiz” to health@chronicle.org.
NPC Healthbiz Weekly is published by Chronicle Companies, 701 Ellicott Street, Buffalo, N.Y. 14203. Canadian Office: 1460 The Queensway, Suite 212, Etobicoke, Ont. M8Z 1S4
Mitchell Shannon, Publisher; R. Allan Ryan, Editorial Director; John Evans, Kylie Rebernik, Jeremy Visser, Editors; Cristela Tello Ruiz, New Business Development
Content is copyright (c) 2023, Chronicle LifeSci America Corp., except as indicated. Are you interested in contributing to this newsletter or learning about Chronicle’s services? Please write to us at health@chronicle.org.
Thanks for reading NPC Healthbiz Weekly. Be sure to subscribe to receive new posts directly to your inbox.